Tuesday, 2 August 2011

Lab-on-a-chip can be game-changer in disease detection

A cheap, highly portable blood test has published a study Sunday so just like expensive hospital-based analysis for the detection of HIV, syphilis and other infectious diseases, proved its worth.

Researchers tested prototypes of the credit card size lab-on-a-chip with hundreds of patients in Rwanda, reporting almost 100 percent accuracy.

The so called "mChip", said could help translate three obstacles to the effective delivery of health care in the poorest regions of the world: difficult access, high costs and long delays for results.

"The idea is, a large class of diagnostic tests in each setting in the world, rather than they force to go, to a clinic to draw blood and then wait to make patient days for their results," said Samuel SIA, a professor at Columbia University and lead developer.

The results were published in Nature Medicine.

With projected production costs of one dollar per unit, it would be mChip far cheaper to administer than current lab-based testing.

Because in several proteins can scan each correspond to a disease, with a single blood sample at the same time it is probably still billiger-and genauer--strips as the work such as pregnancy testsstore-bought.

"Current HIV rapid tests require subjective interpretation of the band intensity by the user, which may lead to false positives", noticed that is healthy individuals is incorrectly diagnosed the study.

The mChip can be in contrast to measure with a hundred-dollar handheld instrument not more complicated to use than a mobile phone, according to the researchers.

Finally, the device delivers results in minutes rather than days or weeks, a time-saving can be a big difference in outcomes.

The device contains a microchip within an injection molded plastic housing located, explains Vincent Chief technological officer at Claros Diagnostics, owns or has licensed relevant patents Linder.

Bind unique disease "Biomarkers" in a pin down blood sample contained to one of up to 10 individual zones.

A nano-scale gold "Reagent" - which is a substance by a chemical reaction - is injected followed by a silver one with gold, an ultra-thin film produce interacts.

"The darkness of the film is proportional to the concentration of biomarkers in the sample", said the steps to the process of development in non-digital photography compare Linder.

With a LED-based detector measured are, or can be evaluated by the naked eye.

In Rwanda SIA and colleagues tested the device in the Muhima hospital in Kigali, where local results take at present days or weeks as samples to an external laboratory must be sent.

Half and half, only tested by a total of 70 copies with known HIV status false, a result, the accuracy of HIV test environment analysis rivals.

Similar tests on more than 100 archived copies equally reliable results gezeitigt such as further studies based on samples of female sex workers are known to be infected with HIV and syphilis.

The researchers hope that it will boost testing of pregnant women, particularly in Africa.

Currently just under a quarter of pregnant women in low and middle income countries are tested for HIV, a number, which offers little hope by 2015 to reach the UN target of elimination of mother-to child transmission according to the 2010 UNAIDS report on the global AIDS epidemic.

You get HIV tests, according to the report present in Zambia and the Democratic Republic of the Congo, for example, only nine and six percent, or pregnant women.

N.R.C. lower estimate which would die in meltdown

Error in deserializing body of reply message for operation 'Translate'. The maximum string content length quota (8192) has been exceeded while reading XML data. This quota may be increased by changing the MaxStringContentLength property on the XmlDictionaryReaderQuotas object used when creating the XML reader. Line 1, position 8826.
Error in deserializing body of reply message for operation 'Translate'. The maximum string content length quota (8192) has been exceeded while reading XML data. This quota may be increased by changing the MaxStringContentLength property on the XmlDictionaryReaderQuotas object used when creating the XML reader. Line 1, position 9219.

ROCKVILLE, Md. — The Nuclear Regulatory Commission is approaching completion of an ambitious study that concludes that a meltdown at a typical American reactor would lead to far fewer deaths than previously assumed.

The conclusion, to be published in April after six years of work, is based largely on a radical revision of projections of how much and how quickly cesium 137, a radioactive material that is created when uranium is split, could escape from a nuclear plant after a core meltdown. In past studies, researchers estimated that 60 percent of a reactor core’s cesium inventory could escape; the new estimate is only 1 to 2 percent.

A draft version of the report was provided to The New York Times by the Union of Concerned Scientists, a nuclear watchdog group that has long been critical of the commission’s risk assessments and obtained it through a Freedom of Information Act request. Since the recent triple meltdown at the Fukushima Daiichi nuclear plant in Japan, such groups have been arguing that the commission urgently needs to tighten safeguards for new and aging plants in the United States.

The report is a synthesis of 20 years of computer studies and engineering analyses, stated in complex mathematical terms. In essence, it states that if a prolonged loss of electric power caused a typical American reactor core to melt down, the great bulk of the radioactive material released would remain inside the building even when the reactor’s containment shell was breached.

Big releases of radioactive material would not be immediate, and people within a 10-mile radius would have enough time to evacuate, the study found. The chance of a death from acute radiation exposure within 10 miles is therefore near zero, the study projects, although some people would receive doses high enough to cause fatal cancers in decades to come.

One person in every 4,348 living within 10 miles would be expected to develop a “latent cancer” as a result of radiation exposure, compared with one in 167 in previous estimates.

“Accidents progress more slowly, in some cases much more slowly, than previously assumed,” Charles G. Tinkler, a senior adviser for research on severe accidents and one of the study’s authors, said in an interview at a commission office building here. “Releases are smaller, and in some cases much smaller, of certain key radioactive materials.”

The N.R.C. did not intend to release the report until next spring and said its conclusions were still being adjusted after a peer review.

The health effects of a catastrophic meltdown were hypothetical until the 1979 accident at Three Mile Island. That destroyed a billion-dollar reactor but caused no apparent physical harm to nearby residents, immediately or over time. Debate has persisted over whether the United States skirted a disaster or whether that accident was about as bad as it could get.

Edwin Lyman, a nuclear physicist with the Union of Concerned Scientists, contends that the nuclear commission has consistently painted an overly rosy picture and that its latest study does as well. He noted that the study assumed a successful evacuation of 99.5 percent of the people within 10 miles, for example. The report also assumes “average” weather conditions, he noted.

But if a rainstorm were under way during a release of radioactive materials, he said, it could wash contaminants out of the air into a small area, producing a high dose there.

Jennifer L. Uhle, the deputy director of the commission’s office of nuclear regulatory research, said the report was intended to present the “best estimate” and not the worst case.

Dr. Lyman said the earlier estimate was of a different accident, a major pipe break. The new study considered that accident too unlikely to analyze.

Dr. Lyman suggested that in projections of fatal cancer cases, the focus should be on people who live within 50 miles. The average population within 10 miles of an American nuclear plant is 62,000; within 50 miles, it is about five million.

The commission’s old projection of eventual cancer deaths was one for every 2,128 people exposed within 50 miles; the new study projects one cancer death for every 6,250 people exposed, which still comes to hundreds of cancer deaths within the 50-mile circle, in addition to the hundreds of thousands who would be expected to die of cancer from other causes.

Dr. Lyman countered that when dealing with estimates based on so many variables — including more than 100 reactors of different designs and vintage, in areas with disparate population densities — a difference of a factor of three is not important. In his view, the study reconfirms that reactors pose serious risks.

The commission’s shift in thinking about how much radioactive cesium 137 would escape after a core meltdown is based on a conclusion that most of it would either dissolve in water that stays put or adhere to surfaces within the plant. The authors said previous analyses had made “conservative assumptions” that most of the cesium and other materials would escape. But laboratory studies and computer modeling have not borne out that hypothesis, they said.

Commission experts have said that a total blackout would be extremely rare at an American plant and that backup generators and other machinery would fill the breach until grid power was restored. Nonetheless, the study focused on what would happen in the event of a nuclear station blackout, meaning a complete loss of power from the grid and from backup diesel generators, and then an exhaustion of batteries that supply power, leading to a meltdown. That is what happened at Fukushima.

The study focused on two common reactor types in this country: boiling-water reactors at the Peach Bottom Atomic Power Station in Pennsylvania, similar to those at Fukushima, and pressurized-water reactors at the Surry Power Station in Virginia.

The study gives a highly detailed prediction of which equipment would stop operating; what temperatures, steam pressures and flows of water and steam would result; and where and when leaks would begin after a meltdown.

It concluded that Peach Bottom would not release enough radioactive material to kill anyone immediately, although it could increase the rate of cancer deaths over future decades. At Surry, the probability was so low and the number of people living within 10 miles so small that the death toll would be a fraction of a person.

The report was prepared by staff members of the Nuclear Regulatory Commission and Sandia National Laboratories, a Department of Energy lab. Beyond the revisions to be made as a result of the peer review, the report could undergo further changes after public comments are received next year.

Once completed, it might be used by the commission when it analyzes proposed safety improvements in terms of costs and benefits, or decides where reactors should be located.

“Once we think we know what the best estimate is, we think we can start thinking about applications,” said Jason H. Schaperow, a senior reactor systems engineer and one of the authors.

Confirmed gene patent in cancer test

Error in deserializing body of reply message for operation 'Translate'. The maximum string content length quota (8192) has been exceeded while reading XML data. This quota may be increased by changing the MaxStringContentLength property on the XmlDictionaryReaderQuotas object used when creating the XML reader. Line 1, position 8895.

In a closely watched case, a federal appeals court ruled on Friday that genes can be patented, overturning a lower court decision that had shocked the biotechnology industry.

The Court of appeals for the Federal Circuit, which specializes in patent cases, said that Myriad Genetics which entitled to patents on two human genes used to predict if women have an increased risk of getting breast and ovarian cancer.

The court ruled that DNA isolated from the body which eligible for patents because it was "markedly different" in its chemical structure from DNA that exists inside the chromosomes in the body. As a result, the isolated DNA is not simply a product of nature, which would not be eligible for a patent.

The 2-to-1 decision on the gene of del issue so what a rejection of arguments made by the Obama administration, which had filed a friend of the court brief arguing that isolated DNA should not be patented. That letter went against the long standing policy of the United States Patent and Trademark Office to grant such patents.

The appeals court ruled against myriad in another part of the case, however. The court said that myriad's patent claims on the process of analyzing whether a patient's genes had mutations that raised the risk of cancer which not patentable because it involved only "patent-ineligible abstract mental steps."

The case may eventually reach the Supreme Court.

The decision on the patentability of genes and DNA cheered much, though not all, of the biotechnology industry. Thousands of human genes have been patented, and some biotechnology executives say such patents are essential for encouraging innovation.

"It basically adhered to the policy, the Patent Office has pursued since the early ' 80 of, when the biotech industry was born," said Gerald j. Flattmann Jr., a patent lawyer at Paul Hastings in New York, who represents pharmaceutical companies but which are not involved in this case. "Isolated gene patents are the cornerstone of the biotechnology industry."

Critics say it is unethical to patent something that is part of the human body or the natural world. Some also say that the cost of testing might be reduced if companies did not hold testing monopolies because of their patents. Myriad, which holds the patents on the genes called BRCA1 and BRCA2 genes with the University of Utah Research Foundation, charges more than $3,000 for its breast cancer risk test.

A lawsuit challenging the patents on the breast cancer risk genes which filed in 2009 by the American Civil Liberties Union and the public patent Foundation, acting as the lawyers for various cancer patients, medical researchers and medical societies.

In U.S. on opinion issued in March 2010, District Judge Robert W. sweet in Manhattan ruled the patents were invalid. The importance of DNA, he said, what the information content it carried in terms of how proteins should be made. In that aspect, he said, the isolated DNA was not really different from the DNA in the body. The argument that isolating the DNA made it different, he said, what is just "a lawyer's trick."

But the appellate decision Friday rejected judge sweet's reasoning, saying that since DNA is a chemical, the chemical structure is what matters and that "informational content is irrelevant to that fact."

"The claims cover molecules that are markedly different - have a distinctive chemical identity and nature - from molecules that exist in nature," judge Alan D. Lourie wrote for the court.

Peter D. Meldrum, chief executive of myriad, said Friday that he was "absolutely delighted with the ruling." He said the patent claims that the court ruled invalid were not important and that patent protection for the company's test which is as strong as before the lawsuit which was filed.

Daniel B. Ravicher, executive director of the public patent Foundation, which helped file the suit, called the decision a partial victory for the plaintiffs. 1250–1400 That one judge dissented on the gene patents, he said, "They can't agree among themselves."

Mr. Ravicher said the plaintiffs were considering either asking the entire appellate court to rehear the gene of del aspects of the case or appealing to the Supreme Court.

While judge Lourie's opinion spoke for the court, the other two judges wrote their own opinions.

Judge Kimberly A. Moore agreed that genes were patentable but cited somewhat different reasoning, including that only Congress should change Patent Office policy to grant such patents.

"Judicial restraint is particularly important here because on entire industry developed in the decades since the Patent Office first granted patents to isolated DNA," Judge Moore wrote. "Disturbing the biotechnology industry's settled expectations now risks impeding, not promoting innovation."

But the third judge on the panel, William C. Bryson, dissented, saying that the genes should not be patented just because they were isolated from the body. In some respects, he wrote, "extracting a gene is akin to snapping a leaf from a tree."

Judge Lourie, in the prevailing opinion, rejected that analogy, saying that isolating DNA created a new chemical entity. It what not simply a matter of separating or purifying the DNA, he said, and not like snapping off a leaf or extracting a mineral from the earth.

The patent claims that the appellate court ruled invalid involved analyzing a patient's genes to see if they had deleterious mutations. Many diagnostic tests involve analyzing some gene or chemical in the body, and whether such tests can be patented is an issue that the Supreme Court has agreed to consider in another case.

Lisa A. Haile, a patent lawyer at DLA Piper in San Diego who is not involved in the myriad case, said the appeals court on Friday suggested myriad's claims would have been upheld if there was another step, such as sequencing the genes, in addition to just mental steps.

"You can 't say diagnostic claims aren't' t patentable," Ms. Haile said. "It's just the way these claims were written."

Health highlights: 28 July 2011

Here some of the latest health and medical news are compiled by the editors of HealthDay developments:

New Brain Scan technique shows back pain severity

Doctors help a new brain of imaging technology to determine and monitor the severity of patient's back pain, the researchers say.

They found that the method called arterial spin labeling and they carried out during MRI images, observe changes in blood flow in certain areas of the brain as chronic back pain patients uncomfortable positions enabled, ABC News reported.

The study was conducted by scientists at Brigham and women's Hospital in Boston and is online and in the August print issue of the journal Anesthesiology.

"Usually, if you do studies with older techniques, you are not able to track the changes in human chronic pain in the course of time" study selection Dr. Ajay D. Wasan, Assistant Professor of Anesthesiology and Psychiatry, said ABC News. "This provides a way to see the physiology of the brain if someone has more or less chronic pain."

-----

Judge has suit apart from embryonic stem cell research

The Obama administration are still the funding of research into embryonic stem cells to an action on it Wednesday was released.

The suit alleges that a federal law prohibits, the taxpayer, which was financing of embryonic stem cells injured by the US national institutes of health research, which damages an embryo. But the Obama administration argues that the Federal Republic allows research using reported directive of embryos that have been harvested long ago, through private funding, the Associated Press .

US district judge Royce Lamberth decided last year that the action was probably successfully and a stop federally funded embryonic research ordered while the case further. But the U.S. Circuit Court of appeals in Washington, D.C. decided, that the action was a probable failure and the injunction lifted.

As a result reported Lamberth a statement on behalf of the Obama administration Wednesday AP released.

Scientists hope that cures for a range of diseases, including spinal cord injuries and Parkinson's diseaseavailable is the embryonic stem cells a day.

-----

Little evidence of 9 / 11 cancer link: report

A report released Tuesday saying U.S. Government it is not enough evidence to determine whether dust and smoke caused cancer causing terrorist attack on the World Trade Center in rescue and recovery workers or New York City residents who lived in the vicinity at the moment.

The finding means that their disease, says people with cancer diagnostics that they attribute the 9/11 attack qualify for federal benefits to treat or compensate for the New York Times.

The report by the National Institute for occupational safety and health was a new federal law required, which offers to monitor $4.3 billion in the next five years, to treat and to compensate for people who were exposed to dust and fumes from the WTC attack.

Proven on an assessment of the available data, the report is based, but there were only 18 published studies of the WTC attack, the cancer mentioned. Only five of these studies were peer-review and she showed mixed results, according to NIOSH Director Dr. John Howard, The Times reported.

A second review of a possible link between cancer and the WTC attack in beginning until mid 2012 is led, said Howard.

According to the timessome doctors believe that a link to cancer with time will be created.

Dr. Philip j. Landrigan, Director of the programme dedicated to 9/11 treatment, surveillance and research at Mount Sinai Medical Center, said the newspaper, that the likelihood of cancer tied increases as years pass on 9 / 11. He referred to his team research in multiple myeloma, which seems at a rate higher than usual, and at an unusually young age in some responders occur.

-----

MedicalNewsCopyright © 2011 HealthDay. All rights reserved.


Vital signs: risks: women's cancer risk increases with height, study

A woman is ever greater, your risk for canceris the greater, a large-scale study.

Researchers at the University of Oxford in England analyzed data on more than 1.2 million British women for an average 9.4 years followed. There were more than 97,000 cases of cancer among women. The researchers found that for every four-inch increase in the height of more than 5 feet 1 inch, the risk that a woman by around 16 per cent increase would cancer. The study was published online July 21 in the Lancet Oncology.

The analysis covers the 17 types of cancer, but the relative risk increase is statistically significant for only 10 of them. The authors suggest that levels of growth hormone on the development of cancer could be involved in or higher people are simply vulnerable to mutations because their bodies include more cells.

The authors reviewed previous studies showing that a similar connection between height and an increased risk of cancer in Asia, Australasia, Europe and North America has been observed.

"There is interest in this study he us a clue about how cancer could develop,", said Jane Green, the lead author and an epidemiologist at Oxford. "It is the similarity to many different types of cancer in people with many different risk factors, and in many different populations, which makes us think that it is something very important in the development of cancer."

Report could tighten the FDA oversight of medical devices.

By Amanda Gardner
HealthDay reporter

Thursday, July 28 HealthDay News)-the US Institute of medicine plans to release a report Friday that could change the way, the medical devices are regulated.

The report anticipated U.S. food and drug was requested by the Administration 2009 and is expected to recommend that a rigorous approval process through medical products such as artificial joints and pacemakers, before go to the market.

Consumer interest groups were critical FDA oversight of medical devices, argued that they were usually too quickly deleted.

"FDA oversight and review process is too weak and must be strengthened," said Dr. Michael Carome, Deputy Director of public citizen health research group.

What to at issue in the upcoming Institute of Medicine (IOM) report to be, it seems, is the accelerated 510(k)-Prozess of device approval, under which come the medical devices on the market.

This process accelerated approval of devices when they are "substantially equivalent" to an existing device.

Published reports suggest that the majority of the medical equipment or about 3,000 are annually, led in this way.

A minority of higher risk devices, such as heart implanted defibrillators, have to go through a stringent approval process not unlike the new drug required.

Patient safety advocates say that too many appliances under the 510(k) program, the system deletes is from the outset too lax.

"We believe that the process for the approval of devices in the programme 510(k) frequently inadequate, due to the application and the loose interpretation of what it means is"device much be same to a predicate", said Carome."

But industry groups say that the program calls the required devices for patients much faster and brings a campaign in Washington, D.C., to doubts about the report, before it's released, the New York Times reported.

The IOM report follows several recalls of devices, including the recall last year of two artificial hip systems, which was been planted nearly 100,000 patients commonly known.

In the meantime, the FDA reported two warnings to surgical mesh devices in three years, issued support MSNBC has the view bodies, such as the bubble.

MedicalNewsCopyright © 2011 HealthDay. All rights reserved.

Sources: Michael Carome, m.d., Deputy Director, health research group, public citizen, Washington, D.C.; The New York Times; MSNBC


Monday, 1 August 2011

CDC: Strokes, rise in pregnant women, new moms

Strokes have suffering to pregnant women and new mothers, probably spiked heel, because more of them are overweight and high blood pressure and heart disease, researchers from report in the United States.

Hospitalizations for pregnancy-related strokes and "Mini strokes" jumped from about 4,100 1994-95 to around 6,300 2006-07, an increase of 54% researchers said, extrapolation of numbers in a large database of the Federal Republic.

"This is a very, very trigger alarm statistics, we need to take that very seriously", said Dr. Olajide Williams, neurologist at Columbia University, and Harlem hospital and an American Stroke Association spokesman. "We need more aggressive in screening-are these women for these risk factors."

The number of strokes is small, when you consider that about 4 million babies are born each year in the United States but pregnancy raises risk of stroke due to the all a woman hormone and blood changes that occur. When it unhealthy, starts with a problem such as diabetes or high blood pressure, she doubled their risk of suffering a stroke during or directly after pregnancy, said Dr. Elena Kuklina, stroke prevention experts at the Centers for disease control and prevention.

They led the study, published Thursday in the journal of the American Heart Association stroke.

Researchers records used from a sample of hospitals in almost all countries, for up to 8 million hospitalizations each year. She saw the number of women, the strokes and transient ischaemic attacks - TIAs or 'Mini strokes' - during pregnancy or in the three months after the birth.

Prices were highest in the South and lowest in the Northeast.

Researchers also saw the prevalence of high blood pressure and heart disease, health problems associated with obesity, and came to the conclusion that this almost all the increase in stroke-related hospitalizations taken into account. Researchers also noted that women later children have, and the risk of a stroke increases with age.

Sometimes pregnant women and new moms so focused on the baby health, the neglect they consider their own, said Williams.

"Think special rooms, which are going to color it to paint rooms on baby names." You have maternity think, "said Williams." "But an ounce of prevention is always the best recipe for a healthy life."

Kuklina agreed.

"If you are planning a pregnancy, try to see your doctor before you pregnant" advised them to stroke risks are examined. And if you are pregnant, "try as early as possible to start your prenatal care." "It is important, healthy living, have healthy diets, smoking quit, if you smoke, are, increase your physical activity and further maintain your healthy weight before pregnancy and during pregnancy."

CDC reported this year researchers with same data sets hospitalization that strokes increase dramatically in young and middle age while fall into Americans in older people, a sign that the obesity epidemic, to shift the age burden of the disease cannot be started.

Getting help fast, as soon as symptoms occur, is to prevent key to the long-term detriment. The warning signs of a stroke are sudden, this: numbness or weakness on one side, severe headache without known cause, to talk about walking, confusion and trouble or to see.

___

___

Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP.

Twitter Delicious Facebook Digg Stumbleupon Favorites More

 
Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | coupon codes